Tirzepatide vs CJC-1295 (No DAC)

Metabolic versus growth-hormone research peptides. Here is how the two research peptides compare on class, format and price.

Tirzepatide

Tirzepatide is a synthetic peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It is supplied lyophilised in a 10 mg vial for laboratory and in-vitro research use only.

Tirzepatide is studied in metabolic-signalling research for its combined activity at two incretin receptors, and is frequently compared with single-agonist peptides and with the triple agonist Retatrutide.

CJC-1295 (No DAC)

CJC-1295 without DAC (Mod GRF 1-29) is a synthetic analogue of growth-hormone-releasing hormone. It is supplied lyophilised in a 10 mg vial for laboratory and in-vitro research use only.

CJC-1295 (No DAC) is studied for GHRH-receptor signalling and is frequently researched alongside the GHRP peptide Ipamorelin, with which it is often combined.

Which do researchers choose?

Tirzepatide and CJC-1295 (No DAC) are metabolic versus growth-hormone research peptides. The right choice depends on the research question: they differ in class (GIP / GLP-1 receptor co-agonist vs Mod GRF (1-29) GHRH analogue) and strength (10 mg vs 10 mg). Both are supplied lyophilised, third-party HPLC tested, and shipped express post Australia-wide for laboratory and in-vitro research use only.

Frequently asked questions